Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA

Update: 2020-01-23

Description

Atul Deodhar, from the Oregon Health & Science University, provides an overview of recent clinical trial results in the area of seronegative Spondylarthritis. He presented the 24-week data of Guselkumab in active psoriatic arthritis patients in the DISCOVER-1 study and compared the phase 3 trials in non-radiographic SpA patients on Ixekizumab (COAST-X) and Secukinumab (PREVENT) with up to 52 week data available.

Comments

In Channel

Use of imaging in large vessel vasculitis: EULAR 2023 update

2024-06-2131:43

Managing Systemic Lupus Erythematosus: the latest EULAR recommendations

2024-04-2221:25

A non-pharma approach in systemic lupus erythematosus and systemic sclerosis

2023-10-3018:55

Innate Lymphoid Cells link TGFb and fibrotic pathways in systemic sclerosis skin

2022-02-0721:41

Immunogenicity of anti-SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases

2021-07-2920:37

The EULAR COVID-19 database and its insights into risk factors

2021-03-1825:43

Predictors of disease worsening in systemic sclerosis

2020-09-1511:34

Treating Cytokine Storm Syndrome in COVID-19 patients with glucocorticoids and tocilizumab

2020-08-0623:52

The dose dependent effect of statins on osteoporosis

2020-04-2212:06

A prediction score for individuals at risk to develop rheumatoid arthritis

2020-03-2512:06

Prediction of radiographic progression using synovitis characteristics

2020-03-0610:15

Six-week treatment with low-dose prednisolone in patients with painful hand osteoarthritis

2020-02-1803:08

Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA

2020-01-2314:56

TULIP 2: Efficacy and Safety of Anifrolumab in Patients

2019-12-2303:52

TULIP 1 - highlights from the ACR meeting

2019-12-1004:51

Capture Hi-C reveals novel drug targets in rheumatic diseases

2019-08-2214:03

EULAR recommendations for the management of systemic lupus erythematosus

2019-07-1210:05

Musculoskeletal diseases on the rise worldwide and affecting developed countries the most

2019-06-0313:18

Three tips to get your manuscript published by ARD

2018-08-2904:40

Early inflammatory arthritis outcomes: what changed in the new millennium?

2018-07-1009:58

00:00

Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA

#box-pro-ellipsis-176048210475868{-webkit-line-clamp:2;}Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA

Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA

BMJ Group

Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA